Cart (0 Items)
Your cart is currently empty.
View ProductsUblituximab Biosimilar – Anti-MS4A1, CD20 mAb – Research Grade
| Size | |
|---|---|
| Brand | |
| Product type | |
| Clonality | |
| Expression system | |
| Applications |
| Product name | Ublituximab Biosimilar - Anti-MS4A1, CD20 mAb - Research Grade |
|---|---|
| Source | CAS 1174014-05-1 |
| Species | Chimeric |
| Expression system | Mammalian cells |
| Purity | >85% |
| Buffer | PBS buffer PH7.5 |
| Delivery condition | Blue ice (+4°C) |
| Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
| Storage condition | store at -80°C |
| Brand | ProteoGenix |
| Applications | ELISA,WB |
| Aliases /Synonyms | Ublituximab,LFB-R603, TG-1101,TGTX-1101,MS4A1, CD20,anti-MS4A1, CD20 |
| Reference | PX-TA1264 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | IgG1-kappa |
| Clonality | Monoclonal Antibody |
Description of Ublituximab Biosimilar - Anti-MS4A1/CD20 mAb - Research Grade
General information on Anti-MS4A1/CD20[Homo sapiens] (Ublituximab) Monoclonal Antibody
Ublituximab has been investigated for the treatment of B-cell Lymphoma, Neuromyelitis Optica, Mantle Cell Lymphoma, Non-Hodgkins Lymphoma, and Marginal Zone Lymphoma.
Related products
Antigen
CD20 Protein – Human CD20 Recombinant Protein
PX-P3060 210€
SIL
Reviews
Il n’y a pas encore d’avis.